Get the Stockscreener App
100.68
1.87%
1.85
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $100.68, with a volume of 19.81M.
It is up +1.87% in the last 24 hours and up +13.76% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$98.83
Open:
$101
24h Volume:
19.81M
Relative Volume:
1.46
Market Cap:
$175.37B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
28.05
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+7.19%
1M Performance:
+13.76%
6M Performance:
-17.31%
1Y Performance:
-16.46%
1-Day Range:
$99.47
$102.13
1-Week Range:
$87.64
$102.13
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
100.68 | 172.14B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
319.87 | 126.97B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.20 | 106.96B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.03 | 66.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.73 | 50.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Stock: Bear Trap Over, With Richer Return Prospects (NYSE:ABT) - Seeking Alpha
Abbott Just Showed Its Growth Engine Has More Than One Cylinder - Trefis
Abbott investigates two cyber intrusions targeting cancer diagnostics and LabCentral portal - Межа. Новини України.
Abbott investigates two separate cyber incidents, says no operations affected By Reuters - Investing.com
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Keysight Invalidates IRS Rule On GILTI, Abbott Says - Law360
Abbott probes two cyber incidents amid extortion claims - BleepingComputer
Abbott discloses cyberattack on cancer diagnostics business - MedTech Dive
ABT Reiterated by Piper Sandler -- Price Target Raised to $118 - GuruFocus
Can Abbott Laboratories (NYSE:ABT) Extend Its Dividend Strength? - Kalkine Media
Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance - TIKR.com
Abbott Laboratories Stock (ABT) Moved Up by 3.03% on Jul 17: Drivers Behind the Movement - TradingKey
ABT Q2 Earnings Call Flags Stronger Second-Half Setup - The Globe and Mail
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results - Benzinga
Benchmark reiterates Buy on Abbott Labs stock, keeps $120 target - Investing.com
Can Abbott Stock Deliver on Its Second-Half Growth Promise? - Trefis
Abbott Laboratories stock could rise 40%+ by 20... - Pluang
JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight Rating - marketscreener.com
Bernstein Adjusts Price Target on Abbott Laboratories to $117 From $110, Maintains Outperform Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform Rating - marketscreener.com
Abbott Laboratories: Pick Up This Dividend King Deal Now - Seeking Alpha
Raising Dividends for 54 Consecutive Years to Reward Shareholders, Abbott Laboratories’ Diversified Layout Consolidates Its Growth Foundation - NAI500
What Helped Abbott Laboratories (NYSE:ABT) Raise Full-Year Outlook? - Kalkine Media
Abbott Laboratories (ABT) Could Be 15% Undervalued On Raised 2026 Earnings Outlook - simplywall.st
Why Abbott Stock Jumped Today - The Motley Fool
Abbott Laboratories Earnings Call Signals Broad-Based Momentum - TipRanks
ABT: Abbott Laboratories Exceeds Revenue and EPS Expectations, R - GuruFocus
Abbott Is On Deck to Launch Several New Devices - Morningstar
ABT: Abbott Laboratories Exceeds Expectations and Raises Profit Outlook - GuruFocus
Abbott Laboratories’s Stock Price Soars to $98.83, Enjoying a Robust 10.71% Uptick - Smartkarma
Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off - The Motley Fool
BTIG raises Abbott Labs stock price target to $134 on Q2 strength - Investing.com
Strong Demand and Growth Forecast for Abbott Laboratories (ABT) - GuruFocus
Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Stro - GuruFocus
Abbott (ABT) Lifts 2026 EPS Outlook Amid Business Mix Shift Toward Devices and Diagnostics - Yahoo Finance
Abbott (ABT) Receives Outperform Rating Amid Positive Q2 Results - GuruFocus
Abbott Surges 11% After Boosting 2026 Profit Outlook - Investor's Business Daily
Abbott Laboratories Stock Draws Fresh Targets As Growth Story Builds - StocksToTrade
Abbott Laboratories (ABT) Surges on Upbeat Q2 Earnings and Revis - GuruFocus
Wells Fargo Raises Abbott Laboratories Price Target to $112 From $109 - marketscreener.com
Abbott Stock Is Leading the S&P 500 After Earnings for Its Best Day in 24 Years - Barron's
How Abbott Laboratories (ABT) performed in Q2 2026 - AlphaStreet
Abbott Labs Draws Bullish Targets As Legal Overhang Fades - timothysykes.com
Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news
Abbott Laboratories (ABT) Shares Surge Over 10% After Strong Q2 Earnings - GuruFocus
Abbott Laboratories Draws Bullish Targets As Legal Overhang Eases - StocksToTrade
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street - MarketBeat
Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise - marketscreener.com
Why Is Abbott Stock Skyrocketing Thursday?Abbott Laboratories (NYSE:ABT) - Benzinga
Abbott Laboratories Raises Full-Year Earnings Guidance as Second-Quarter Results Top Views - Moomoo
Abbott stock powers through 100-DMA, but long-term downtrend still looms (ABT:NYSE) - Seeking Alpha
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):